
PRESS RELEASE



For Immediate Release

Contact: info@globalcancertechnology.com

GLOBAL CANCER TECHNOLOGY RECEIVES EURASIAN GRANT OF LICENSED PATENT

GCT-008, A POTENT VPS34 INHIBITOR NOW PROTECTED IN EURASIAN COUNTRIES

San Diego, CA, August 1, 2023 – Global Cancer Technology, Inc. announced today that GCT-008, an inhibitor of vacuolar protein sorting 34 (VPS34), was granted protection status by the Eurasian Patent Organization (EAPO), which issued Patent Certificate No. 043225. VPS34 is an important inhibitor of autophagy, a process often used by cancer cells to avoid effective treatment with chemotherapy. “We are pleased to add GCT-008 to our arsenal of anti-cancer drugs,” said Dr. M. Karen Newell-Rogers, chief scientific advisor to Global Cancer Technology. Global Cancer Technology has an exclusive world-wide license for GCT-008 from Neuropore Therapies, Inc.

“We are delighted to have this patent protection issued by the Eurasian Patent Organization”, said John Clark, the CEO of Global Cancer Technology. Mr. Clark further stated that “We now have issued protection in the countries of Armenia, Azerbaijan, Belarus, Kazakhstan, Russia and Tajikistan and we will continue to expand our worldwide IP protection for GCT-008”.

Global Cancer Technology is a Company developing 2 promising targeting immunotherapy drugs: GCT-007, a PI3K inhibitor and GCT-008, a VPS34 inhibitor.

Global Cancer Technology is a pre-clinical non-revenue biopharma company that is currently raising investment capital to enter a Phase 1 clinical trial (globalcancertechnology.com). Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.